The cumulative token total was estimated at about $27 million on Oct. 23.
Positions can draw on shared collateral. NEAR says deposits and withdrawals to and from dedicated accounts are confidential, while Hyperliquid trading activity is recorded onchain.
Hyperliquid Strategies raises its share repurchase authorization to $100 million, with $72 million remaining available through October 2027.
Regulatory challenges may hinder Hyperliquid's U.S. market entry, affecting investor sentiment and necessitating compliance adaptations. CME CEO: Hyperliquid faces US market entry hurdles over KYC issues.
The net buy-side lead equaled 96.12% of combined depth. A bid at $81,800 was worth about $16.48 million.
A HYPE short valued at about $2.53 million showed an unrealized loss of about $39,700. Boomer's account had an overall unrealized gain alongside cumulative losses over the past 30 days.
Hyperliquid Strategies increases its stock buyback authorization to $100 million as PURR shares decline over 30% and HYPE falls more than 18%. Hyperliquid Strategies expands stock buyback program to $100M as PURR shares fall over 30%.
The positions were in HIP-3 contracts tied to U.S. stocks, with new exposure on each asset topping $500,000.
Hayes sees real demand for on-chain perpetual futures but says similar rival offerings have weakened HYPE's investment appeal.
Most HIP-3 perpetual markets are expected to see roughly twice as much volume count toward L1 user rate limits. Fee-tier volume calculations will remain unchanged.
About 362,000 contract units traded in the three hours after Moderna's cancer-vaccine clinical data surfaced. Notional open interest later returned near its pre-event level.
Shorts made up 53.78% of the positions, compared with 46.22% for longs; the long-to-short ratio was 0.86.